According to Jefferies, Dynavax Technologies DVAX is seeing a favorable ACIP stance for diabetes vaccination mandate.
Jefferies said that, at the CDC's ACIP meeting, the hepatitis working group recommended a broad mandate to vaccinate all diabetics up to the age of 60 for hepatitis B (HBV). “We view this as a positive as it opens up a large market opportunity for DVAX's Heplisav HBV vaccine, and we see upside potential for even broader use in all diabetics. We expect Heplisav approval in early 2013.”
Dynavax Technologies closed yesterday at $2.65.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in